1. |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2019. V1). 北京: 人民卫生出版社, 2019.
|
2. |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol, 2014, 15(6): 640-647.
|
3. |
Untch M, Thomssen C, Bauerfeind I, et al. Primary therapy of early breast cancer: Evidence, controversies, consensus: spectrum of opinion of German specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd, 2019, 79(6): 591-604.
|
4. |
中国乳腺癌新辅助治疗专家组. 中国乳腺癌新辅助治疗专家共识(2019 年版). 中国癌症杂志, 2019, 29(5): 390-400.
|
5. |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17(6): 791-800.
|
6. |
李文金. 乳癌新辅助化疗后 Ki-67 变化与临床疗效的关系. 齐鲁医学杂志, 2017, 32(1): 23-24, 27.
|
7. |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2020. V1). 北京: 人民卫生出版社, 2020.
|
8. |
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med, 2019, 380(7): 617-628.
|
9. |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010, 375(9712): 377-384.
|
10. |
Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 2018, 19(1): 115-126.
|
11. |
van Ramshorst MS, van Werkhoven E, Honkoop AH, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast, 2016, 29: 153-159.
|
12. |
Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase Ⅲ KRISTINE study. J Clin Oncol, 2019, 37(25): 2206-2216.
|
13. |
Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase Ⅱ TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer, 2018, 89: 27-35.
|
14. |
van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 2018, 19(12): 1630-1640.
|
15. |
谭惠文, 李佳琦, 余叶蓉, 等. 多学科专家团队模式在垂体瘤及相关疾病诊疗中的应用. 华西医学, 2018, 33(12): 1526-1529.
|
16. |
杨彬. 多学科模式在乳腺癌诊治中的实践及新进展. 中国医药导报, 2019, 16(26): 54-56, 63.
|
17. |
Prabhakar CN, Fong KM, Peake MD, et al. The effectiveness of lung cancer MDT and the role of respiratory physicians. Respirology, 2015, 20(6): 884-888.
|
18. |
王朋飞, 代伟娜, 刘礼新, 等. 多学科联合胸腔镜手术治疗肺癌的应用分析. 中国胸心血管外科临床杂志, 2019, 26(12): 1185-1189.
|
19. |
Taylor C, Munro AJ, Glynne-Jones R, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ, 2010, 340: c951.
|